Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2004-06-16
2009-08-04
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094100, C424S009100, C514S002600, C530S350000, C435S253400, C536S023200
Reexamination Certificate
active
07569223
ABSTRACT:
The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment ofStreptococcus pneumoniabacteria and spores, and related conditions. The disclosure further relates to methods and compositions for the identification of a phage associated lytic enzyme to rapidly killStreptococcus pneumoniaeand other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure to,Streptococcus pneumoniaeare also provided.
REFERENCES:
patent: 3278378 (1966-10-01), Schindler et al.
patent: 3398056 (1968-08-01), Zygmunt et al.
patent: 3594284 (1971-07-01), Zygmunt et al.
patent: 4615697 (1986-10-01), Robinson
patent: 4948580 (1990-08-01), Browning
patent: 5413792 (1995-05-01), Ninomiya et al.
patent: 5554380 (1996-09-01), Cuca et al.
patent: 5604109 (1997-02-01), Fischetti et al.
patent: 5808022 (1998-09-01), Huse
patent: 5942243 (1999-08-01), Shah
patent: 5976862 (1999-11-01), Kauffman et al.
patent: 5985271 (1999-11-01), Fischetti et al.
patent: 6017528 (2000-01-01), Fischetti et al.
patent: 6056954 (2000-05-01), Fischetti et al.
patent: 6056955 (2000-05-01), Fischetti et al.
patent: 6132970 (2000-10-01), Stemmer
patent: 6238661 (2001-05-01), Fischetti et al.
patent: 6248324 (2001-06-01), Fischetti et al.
patent: 6254866 (2001-07-01), Fischetti et al.
patent: 6264945 (2001-07-01), Fischetti et al.
patent: WO 00/32825 (2000-06-01), None
Altschul et al.; “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs;” Nucleic Acids Res; 25:3389-3402 (1997).
Arkin et al., “An algorithm for protein engineering: Simulations of recursive ensemble mutagenesis,” (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815.
Ausubel et al., eds.;Current Protocols in Molecular Biology; John Wiley & Sons; title page through p. xviii, pp. 16-33 through 16-48; 1992.
Bolton, E. T. et al., “A General Method for the Isolation of RNA Complementary to DNA,” (1962). Proc. Natl. Acad. Sci. USA 48:1390.
Bonner et al., “Reduction in the Rate of DNA Reassociation by Sequence Divergence,” (1973). J. Mol. Biol. 81:123.
Browder et al., “Lysostaphin: Enzymatic Mode of Action,” Res. Comm., 19: 393-400 (1965).
Church, G. M. et al., “Genomic sequencing,” (1988). Proc. Natl. Acad. Sci. USA 81:1991-1995.
Cotton et al., “Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations,” (1985). Proc. Natl. Acad. Sci. USA 85:4397-4401.
Delgrave et al., “Recursive ensemble mutagenesis,” (1993) Protein Engineering 6(3):327-331.
Dixon et al., “Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. III. Combined Lysostaphin-Methicillin Therapy of Established Staphylococcal Abscesses in Mice,” Yale J. Biology and Medicine, 41: 62-68 (1968).
Flavell et al., “Analysis of the β-ô-Globin Gene Loci in Normal and Hb Lepore DNA: Direct Determination of Gene Linkage and Intergene Distance,” (1978). Cell 15:25.
Garcia et al., “Modular organization of the lytic enzymes ofStreptococcus pneumoniaeand its bacteriophages,” Gene 86: 81-88 (1990).
Garcia et al., “Molecular evolution of lytic enzymes ofStreptococcus pneumoniaeand its bacteriophages,” Proc. Natl. Acad. Sci. USA 85: 914-918 (1988).
Garcia, P. et al., “Bacteriophages ofStreptococcus pneumonia: A Molecular Approach,” Microb Drug Resist 3, 165-76 (1997).
Garcia et al.; Streptococcal Genetics (J.J. Ferretti and Curtis eds.; relevant portions: pp. 31-41, 69-72, 93-97, 143-149, 150-152, 177-180, 185-188, 189-192, 205-208, 209-211, 220-224, 225-228 and 250-258; 1987.
Gebeyehu et al., “Novel biotinylated nucleotide—analogs for labeling and colorimetric detection of DNA,” Nucleic Acids Res. 15:4513-4534 1987.
Ghaffar, F. et al., “Dynamics of nasopharyngeal colonization byStreptococcus pneumoniae,” Pediatr Infect Dis J 18, 638-46. (1999).
Gillespie, S. H. et al., “Species of Alpha-Hemolytic Streptococci Possessing a C-Polysaccharide Phosphorylcholine-Containing Antigen,” Infect Immun 61, 3076-7 (1993).
Gleich, S. et al., “Streptococcus pneumoniaeSerotype 4 Outbreak in a Home for the Aged: Report and Review of Recent Outbreaks,” Infect Control Hosp Epidemiol 21, 711-7. (2000).
Haan, L. et al., “Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit ofEscherichia coliheat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity,” Vaccine 19, 2808-907 (2001).
Hausdorff, W.P., “Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part I,” Clin. Infect. Dis. 30 100-21 (2000).
Heikkinen, T. et al., “A single intramuscular dose of ceftriaxone changes nasopharyngeal bacterial flora in children with acute otitis media,” Acta Paediatr 89, 1316-21. (2000).
Ike et al., “Solid phase synthesis of polynucleotides. VIII. Synthesis of mixed oligodeoxyribonucleotides by the phosphotriester solid phase method,” (1983) Nucleic Acid Res. 11:477.
Itakura et al., “Expression inEscherichia coliof a Chemically Synthesized Gene for the Hormone Somatostatin,” (1984) Science 198:1056.
Itakura et al., “Synthesis and Use of Synthetic Oligonucleotides,” (1984) Annu. Rev. Biochem. 53:323.
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences,” Proc. Natl. Acad. Sci. USA, 90:5873-5877 (1993).
Lewin, B.,Genes V, Oxford University Press Chapter 1, pp. 9-13, 1994.
Loeffler, J. M. et al., “Phage Lytic Enzyme Cpl-1 as a Novel Antimicrobial for Pneumococcal Bacteremia,” Infection and Immunity, Nov. 2003, pp. 6199-6204.
Loeffler, J. M. et al., “Rapid Killing ofStreptococcus pneumoniaewith a Bacteriophage Cell Wall Hydrolase,” Science, vol. 294, Dec. 7, 2001, pp. 2170-2172.
Loeffler, J. M. et al., “Synergistic Lethal Effect of a Combination of Phage Lytic Enzymes with Different Activities on Penicillin-Sensitive and -ResistantStreptococcus pneumoniaeStrains,” Antimicrobial Agents and Chemotherapy, Jan. 2003, pp. 375-377.
Loessner, et al., “Evidence for a Holin-Like Protein Gene Fully Embedded Out of Frame in the Endolysin Gene ofStaphylococcus aureusBacteriophage 187,” Journal of Bacteriology, Aug. 1999, p. 4452-4460.
Loessner, M. J., “Heterogeneous endolysins inListeria monocytogenesbacteriophages: a new class of enzymes and evidence for conserved holin genes within the siphoviral lysis cassettes,” Mol Microbiol 16, 1231-41. (1995).
Lopez et al., “Structural analysis and biological significance of the cell wall lytic enzymes ofStreptococcus pneumoniaeand its bacteriophage,” FEMS Microbiol. Lett. 100: 439-448 (1992).
Lopez et al., “The Pneumococcal Cell Wall Degrading Enzymes: A Modular Design to Create New Lysins?,” Microbial Drug Resistance 3: 199:211 (1997).
Mbelle, N. et al., “Immunogenicity and Impact on Nasopharyngeal Carriage of a Nonavalent Pneumococcal Conjugate Vaccine,” J Infect Dis 180, 1171-6. (1999).
Melander, E. et al., “Previous Antibiotic Consumption and Other Risk Factors for Carriage of Penicillin-ResistantStreptococcus pneumoniaein Children,” Eur J Clin Microbiol Infect Dis 17, 834-8. (1998).
Morita, J. Y. et al., “Impact of azithromycin on cropharyngeal carriage of Group A Streptococcus and nasopharyngeal carriage of macrolide-resistantStreptococcus pneumoniae,” Pediatr Infect Dis J 19, 41-6. (2000).
Myers et al., “Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismatches in RNA:DNA Duplexes,” (1985). Science 230:1242.
Myers et al., “Recent Advances in the Devel
Fischetti Vincent A.
Loeffler Jutta M.
Nelson Daniel
Brinks Hofer Gilson & Lione
Kam Chih-Min
The Rockefeller University
LandOfFree
Phage-associated lytic enzymes for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phage-associated lytic enzymes for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phage-associated lytic enzymes for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4082536